KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Deferred Revenue: 2013-2021

Historic Current Deferred Revenue for Xenon Pharmaceuticals (XENE) over the last 3 years, with Sep 2021 value amounting to $2.2 million.

  • Xenon Pharmaceuticals' Current Deferred Revenue fell 70.43% to $2.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $2.2 million, marking a year-over-year decrease of 70.43%. This contributed to the annual value of $3.6 million for FY2020, which is 87.76% down from last year.
  • As of Q3 2021, Xenon Pharmaceuticals' Current Deferred Revenue stood at $2.2 million, which was down 27.21% from $3.0 million recorded in Q2 2021.
  • Over the past 5 years, Xenon Pharmaceuticals' Current Deferred Revenue peaked at $29.7 million during Q4 2019, and registered a low of $2.2 million during Q3 2021.
  • For the 3-year period, Xenon Pharmaceuticals' Current Deferred Revenue averaged around $10.9 million, with its median value being $5.5 million (2020).
  • Data for Xenon Pharmaceuticals' Current Deferred Revenue shows a maximum YoY crashed of 87.76% (in 2020) over the last 5 years.
  • Xenon Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $29.7 million in 2019, then tumbled by 87.76% to $3.6 million in 2020, then tumbled by 70.43% to $2.2 million in 2021.
  • Its Current Deferred Revenue was $2.2 million in Q3 2021, compared to $3.0 million in Q2 2021 and $3.6 million in Q1 2021.